Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page revision tag in the footer was updated from v3.6.5 to v3.6.6. This reflects a minor maintenance update to the page.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe revision label in the page footer updated from v3.6.4 to v3.6.5, indicating a minor page version update. This is a metadata change that does not alter the study information displayed.SummaryDifference0.0%

- Check43 days agoChange DetectedThe footer revision text changed from v3.6.3 to v3.6.4, indicating a new version of the site interface.SummaryDifference0.0%

- Check65 days agoChange DetectedThe record history now lists revision v3.6.3 as the current version, updating the page's metadata.SummaryDifference0.0%

- Check72 days agoChange DetectedThe page's revision label changed from v3.6.0 to v3.6.2. This reflects a new revision published in the history rather than a substantive change to content.SummaryDifference0.0%

- Check87 days agoChange DetectedThe history now shows that enrollment is closed ('No longer looking for participants'), adds a new revision entry 'Revision: v3.6.0', and removes the previous revision entry 'Revision: v3.5.5' from the record.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.